Urticaria is a disease triggered by mast cells and characterized by recurrent symptoms such as wheals and/or angioedema. Most patients benefit from treatment with antihistamines (AH) or, if not effective enough, from additional therapy with omalizumab, which leads to significant symptom relief. Here we present a patient with therapy-resistant chronic spontaneous urticaria treated with AH, omalizumab, and glucocorticosteroids. The subsequent recommended therapy according to the current guideline, cyclosporine A, was contraindicated in this patient. Therefore, therapy with dupilumab was initiated, resulting in a complete control of symptoms. In this case report, we present a case of successful dual therapy with omalizumab and dupilumab.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835203PMC
http://dx.doi.org/10.5414/ALX02382EDOI Listing

Publication Analysis

Top Keywords

case report
8
chronic spontaneous
8
spontaneous urticaria
8
urticaria treated
8
treated omalizumab
8
omalizumab dupilumab
8
therapy omalizumab
8
report severe
4
severe chronic
4
omalizumab
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!